Skip to main content
Log in

Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder

  • Current Opinion
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

This review examines the effects of antidepressant medications on premenstrual dysphoric disorder (PMDD) and the diminished quality of life (QOL) that accompanies the disorder. PMDD is a chronic condition in women that emerges in the second half of the menstrual cycle and remits during the menstrual period. The affective and behavioural symptoms of PMDD adversely affect functioning and QOL to a disabling degree, particularly in the domains of family and personal relationships, work productivity and social activities.

The serotonergic antidepressants, specifically the selective serotonin reuptake inhibitors (SSRIs), are effective for PMDD. Continuous and luteal-phase dosing regimens with SSRIs are similarly effective and well tolerated. Treatment of PMDD with a serotonergic antidepressant significantly improves functioning and QOL in all studies that have systematically examined QOL issues in this disorder.

Although the data show that PMDD is effectively treated with serotonergic antidepressants and that functional impairment that accompanies the disorder is also improved with treatment, the social and economic burden of PMDD continues to be widely unrecognised. Greater awareness of the effectiveness of treatments and reliable measures of the direct and indirect healthcare costs of the disorder when it remains untreated are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. ACOG Practice Bulletin. Premenstrual syndrome. Int J Gynecol Obstet 2001 May; 73 (2): 183–90

    Article  Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 350

    Google Scholar 

  3. Freeman EW, Rickets K, Schweizer E, et al. Relationships between age and symptom severity among women seeking medical treatment for premenstrual symptoms. Psychol Med 1995 Mar; 25 (2): 309–15

    Article  PubMed  CAS  Google Scholar 

  4. Wittchen HU, Becker E, Leib R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002 Jan; 32 (1): 119–32

    Article  PubMed  CAS  Google Scholar 

  5. Freeman EW, Rickets K, Sondheimer SJ. Premenstrual symptoms and dysmenorrhea in relation to emotional distress factors in adolescents. J Psychosom Obstet Gynecol 1993; 14 (1): 41–50

    Article  CAS  Google Scholar 

  6. Sternfeld B, Swindle R, Chawla A, et al. Severity of premenstrual symptoms in a health maintenance organization population. Obstet Gynecol 2002; 99: 1014–24

    Article  PubMed  Google Scholar 

  7. Roca CA, Schmidt PJ, Rubinow DR. A follow-up study of premenstrual syndrome. J Clin Psychiatry 1999; 60: 763–6

    Article  PubMed  CAS  Google Scholar 

  8. Yonkers KA, Barnett LK, Carmody T, et al. Serial discontinuation of SSRI treatment for PMDD [abstract]. Biol Psych 1998; 43 Suppl. 8: 358

    Google Scholar 

  9. de la Gandara Martin JJ. Premenstrual dysphoric disorder: longterm treatment with fluoxetine and discontinuation. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25: 235–42

    Google Scholar 

  10. Freeman EW, Sondheimer SJ, Rickels K, et al. A pilot naturalistic follow-up of extended sertraline treatment for severe premenstrual syndrome. J Clin Psychopharm 2004; 24 (3): 351–3

    Article  Google Scholar 

  11. Angst J, Sellara R, Stolar M, et al. The epidemiology of perimenstrual psychological symptoms. Acta Psychiatr Scand 2001; 104: 110–6

    Article  PubMed  CAS  Google Scholar 

  12. Cohen LS, Scares CN, Otto MW, et al. Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women: the Harvard study of moods and cycles. J Affect Disord 2002; 70 (2): 125–32

    Article  PubMed  Google Scholar 

  13. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women Ment Health 2003; 6: 203–9

    Article  CAS  Google Scholar 

  14. Steiner M, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. CNS Drugs 2000 Apr; 13 (4): 287304

    Article  Google Scholar 

  15. Banerjee N, Roy KK, Takkar D. Premenstrual dysphoric disorder: a study from India. Int J Fertil Womens Med 2000 Sep–Oct; 45 (5): 342–4

    PubMed  CAS  Google Scholar 

  16. Khella AK. Epidemiologic study of premenstrual symptoms. J Egypt Public Health Assoc 1992; 67 (1-2): 109–18

    PubMed  CAS  Google Scholar 

  17. McMaster J, Cormie K, Pitts M. Menstrual and premenstrual experiences of women in a developing country. Health Care Women Int 1997 Nov–Dec; 18 (6: 533–41

    Article  PubMed  CAS  Google Scholar 

  18. Montero P, Bemis C, Loukid M, et al. Characteristics of menstrual cycles in Moroccan girls: prevalence of dysfunctions and associated behaviours. Ann Hum Biol 1999 May-Jun; 26 (3): 243–9

    Article  PubMed  CAS  Google Scholar 

  19. van den Akker OB, Eves FF, Service S, et al. Menstrual cycle symptom reporting in three British ethnic groups. Soc Sci Med 1995 May; 40 (10): 1417–23

    Article  PubMed  Google Scholar 

  20. Chandra PS, Chaturvedi SK. Cultural variations of premenstrual experience. Int J Soc Psychiatry 1989 winter; 35 (4): 343–9

    Article  PubMed  CAS  Google Scholar 

  21. Chang AM, Holroyd E, Chan JP. Premenstrual syndrome in employed Chinese women in Hong Kong. Health Care Women Int 1995 Nov–Dec; 16 (6): 551–61

    Article  PubMed  CAS  Google Scholar 

  22. Merikangas KR, Foeldenyi M, Angst J. The Zurich Study. XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. Fur Arch Psychiatry Clin Neurosci 1993; 243 (1): 23–32

    Article  CAS  Google Scholar 

  23. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000; 61: 101–9

    Article  PubMed  CAS  Google Scholar 

  24. Chawla A, Swindle R, Long S. Premenstrual dysphoric disorder: is there an economic burden of illness? Med Care 2002; 40 (11): 1101–12

    Article  PubMed  Google Scholar 

  25. Morgan M, Rapkin AJ, D’Elia L, et al. Cognitive functioning in premenstrual syndrome. Obstet Gynecol 1996; 88: 961–6

    Article  PubMed  CAS  Google Scholar 

  26. Resnick A, Perry W, Parry B, et al. Neuropsychological performance across the menstrual cycle in women with and without premenstrual dysphoric disorder. Psychiatry Res 1998; 77: 147–58

    Article  PubMed  CAS  Google Scholar 

  27. Robinson RL, Swindle RW. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. J Womens Health 2000; 9 (7): 757–68

    CAS  Google Scholar 

  28. Campbell EM, Peterkin D, O’Grady K, et al. Premenstrual symptoms in general practice patients: prevalence and treatment. J Reprod Med 1997; 42: 637–46

    PubMed  CAS  Google Scholar 

  29. Kuczmierczyk AR, Labrum AIL Johnson CC. Perception of family and work environments in women with premenstrual syndrome. J Psychosom Res 1992; 36: 787–95

    Article  PubMed  CAS  Google Scholar 

  30. Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003; 48: 515–24

    PubMed  Google Scholar 

  31. Hallman J, Georgiev N. The premenstrual syndrome and absence from work due to illness. J Psychosom Obstet Gynaecol 1987; 6: 111–9

    Article  Google Scholar 

  32. Halbreich U, Borenstein J, Pearlstein T, et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28: 1–23

    CAS  Google Scholar 

  33. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Global burden of disease and injury series. Boston: The Harvard School of Public Health, on behalf of the World Health Organization and the World Bank, 1996

    Google Scholar 

  34. Hall RCW, Wise MG. The clinical and financial burden of mood disorders: cost and outcome. Psychosomatics 1995; 36 (2): S11–8

    Article  PubMed  CAS  Google Scholar 

  35. Simon GE, Vonkorff M, Barlow W. Health-care costs of primary-care patients with recognized depression. Arch Gen Psychiatry 1995; 52 (10): 850–6

    Article  PubMed  CAS  Google Scholar 

  36. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992; 267: 1478–83

    Article  PubMed  CAS  Google Scholar 

  37. Horwath E, Johnson J, Klerman GL, et al. Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry 1992; 49: 817–23

    Article  PubMed  CAS  Google Scholar 

  38. Barnard K, Frayne SM, Skinner KM, et al. Health status among women with menstrual symptoms. J Womens Health 2003; 12 (9): 911–9

    Article  Google Scholar 

  39. Rosen LN, Moghadam LZ, Endicott J. Relationship between premenstrual symptoms and general well-being. Psychosomatics 1990 Winter; 31 (1): 47–54

    Article  PubMed  CAS  Google Scholar 

  40. Hartlage SA, Arduino KE, Gehlert S. Premenstrual dysphoric disorder and risk for major depressive disorder: a preliminary study. J Clin Psychol 2001; 57 (12): 1571–8

    Article  PubMed  CAS  Google Scholar 

  41. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998; 44: 839–50

    Article  PubMed  CAS  Google Scholar 

  42. Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000; 256: 1131–6

    Article  Google Scholar 

  43. Wyatt KM, Dimmock PW, O’Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2002; (4): CDO01396

    Google Scholar 

  44. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995; 332: 1529–34

    Article  PubMed  CAS  Google Scholar 

  45. Wood SH, Mortola IF, Chan YF, et al. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol 1992; 80: 339–44

    PubMed  CAS  Google Scholar 

  46. Menkes DB, Taghavi E, Mason PA. Fluoxetine treatment of severe premenstrual syndrome. BMJ 1992; 305: 346–7

    Article  PubMed  CAS  Google Scholar 

  47. Ozeren S, Corakci A, Yucesoy I, et al. Fluoxetine in the treatment of premenstrual syndrome. Fur J Obstet Gynecol Reprod Biol 1997; 73: 167–70

    Article  CAS  Google Scholar 

  48. Pearlstein TB, Stone AB, Lund SA. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997; 17: 261–6

    Article  PubMed  CAS  Google Scholar 

  49. Su TP, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997; 16: 346–56

    Article  PubMed  CAS  Google Scholar 

  50. Cohen LS, Miner C, Brown E, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002; 100: 435–44

    Article  PubMed  CAS  Google Scholar 

  51. Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002 Dec; 100 (6): 121929

    Article  Google Scholar 

  52. Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder. Arch Gen Psychiatry 1999; 56: 932–9

    Article  PubMed  CAS  Google Scholar 

  53. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. JAMA 1997; 278: 983–8

    Article  PubMed  CAS  Google Scholar 

  54. Young SA, Hurt PH, Benedek DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998; 59: 76–80

    Article  PubMed  CAS  Google Scholar 

  55. Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999; 8: 328–32

    Article  PubMed  CAS  Google Scholar 

  56. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58: 399–402

    Article  PubMed  CAS  Google Scholar 

  57. Eriksson E, Hedberg A, Andersch B, et al. The SRI paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology 1995; 12: 167–76

    Article  PubMed  CAS  Google Scholar 

  58. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18: 390–9

    Article  PubMed  CAS  Google Scholar 

  59. Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001; 98: 737–44

    Article  PubMed  CAS  Google Scholar 

  60. Sundblad C, Modigh K, Andersch B, et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand 1992; 85: 39–47

    Article  PubMed  CAS  Google Scholar 

  61. Sundblad C, Hedberg M, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. Neuropsychopharmacology 1993; 9: 133–45

    PubMed  CAS  Google Scholar 

  62. Freeman EW, Rickels K, Sondheimer SJ, et al. Nefazodone in the treatment of premenstrual syndrome: a preliminary study. J Clin Psychopharmacol 1994; 14: 180–6

    Article  PubMed  CAS  Google Scholar 

  63. Freeman EW, Rickels K, Sondheimer SJ. Fluvoxamine for premenstrual dysphoric disorder: a pilot study. J Clin Psychiatry 1996; 57 Suppl. 8: 56–9

    PubMed  Google Scholar 

  64. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992 Apr; 36 (3): 257–66

    Article  PubMed  CAS  Google Scholar 

  65. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001 Jul-Aug; 10 (6): 561–9

    Article  PubMed  CAS  Google Scholar 

  66. Brown CS, Ling FW, Andersen RN, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994 Nov; 84 (5): 779–86

    PubMed  CAS  Google Scholar 

  67. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997; 33 (2): 303–9

    PubMed  CAS  Google Scholar 

  68. Hammarback S, Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome: a double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynecol Scand 1988; 67 (2): 159–66

    Article  PubMed  CAS  Google Scholar 

  69. Hussain SY, Massil III, Matta WH, et al. Buserelin in premenstrual syndrome. Gynecol Endocrinol 1992 Mar; 6 (1): 57–64

    Article  PubMed  CAS  Google Scholar 

  70. Wyatt K, Dimmock P, Jones P, et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001 Oct 6; 323 (7316): 776–80

    Article  PubMed  CAS  Google Scholar 

  71. Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 1994 Sep; 84 (3): 379–85

    PubMed  CAS  Google Scholar 

  72. Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995 Jul 5; 274 (1): 51–7

    Article  PubMed  CAS  Google Scholar 

  73. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam: a controlled study. Arch Gen Psychiatry 1990 Mar; 47 (3): 270–5

    Article  PubMed  CAS  Google Scholar 

  74. Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome [letter]. Lancet 1989 Apr 8; 1 (8641): 777

    Article  PubMed  CAS  Google Scholar 

  75. Smith S, Rinehart IS, Ruddock VE, et al. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987 Jul; 70 (1): 37–43

    PubMed  CAS  Google Scholar 

  76. Dennerstein L, Morse C, Burrows G, et al. Alprazolam in the treatment of premenstrual syndrome. In: Dennerstein L, Fraser I, editors. Hormones and behavior. New York (NY): Elsevier Science Publishing, 1986: 175–82

    Google Scholar 

  77. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993 Jun; 50 (6: 467–73

    Article  PubMed  CAS  Google Scholar 

  78. Thys-Jacobs S, Starkey P, Bernstein D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998 Aug; 179 (2): 444–52

    Article  PubMed  CAS  Google Scholar 

  79. Pearlstein T, Steiner M. Non-antidepressant treatment of premenstrual syndrome. J Clin Psychiatry 2000; 61 Suppl. 12: 227

    Google Scholar 

  80. Stevinson C, Ernst E. Complementary/alternative therapies for premenstrual syndrome: a systematic review of randomized controlled trials. Am J Obstet Gynecol 2001 Jul; 185 (1): 22735

    Article  Google Scholar 

  81. Pearlstein T. Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder. Drugs 2002; 62 (13): 1869–85

    Article  PubMed  CAS  Google Scholar 

  82. Altshuler LL, Cohen LS, Moline ML, et al. The Expert Consensus Guideline Series: treatment of depression in women. Postgrad Med 2001 Mar; (Spec No): 1–107

    Google Scholar 

  83. Freeman EW, Sondheimer SJ, Polansky M, et al. Predictors of response to sertraline treatment of severe premenstrual syndromes. J Clin Psychiatry 2000; 61: 579–84

    Article  PubMed  CAS  Google Scholar 

  84. Sundström-Poromaa I, Bixo M, Björn I, et al. Compliance to antidepressant drug therapy for treatment of premenstrual syndrome. J Psychosom Obstet Gynecol 2000; 21: 205–11

    Article  Google Scholar 

  85. Miner C, Brown E, McCray S, et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002; 24: 417–33

    Article  PubMed  CAS  Google Scholar 

  86. Zajecka J, Tracey KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997; 58 (7): 291–7

    Article  PubMed  CAS  Google Scholar 

  87. Pearlstein T, Gillespie JA. When should premenstrual dosing in PMDD end? [poster]. 155th Annual APA Meeting; 2002 May 18–23, Philadelphia

    Google Scholar 

  88. Clayton AIL Pradko IF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357–66

    Article  PubMed  Google Scholar 

  89. Steiner M, Brown E, Trzepacz P, et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Women Ment Health 2003; 6: 71–7

    Article  CAS  Google Scholar 

  90. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry 1976; 33: 1111–5

    Article  PubMed  CAS  Google Scholar 

  91. Endicott J, Nee J, Harrison W, et al. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321–6

    PubMed  CAS  Google Scholar 

  92. Endicott J, Harrison W. Daily rating of severity of problems form. New York (NY): Department of Research Assessment and Training, New York State Psychiatric Institute, 1990

    Google Scholar 

  93. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 1980; 62: 177–90

    Article  PubMed  CAS  Google Scholar 

  94. Leon AC, Olfson M, Portera L, et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997; 27: 93–105

    Article  PubMed  CAS  Google Scholar 

  95. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000; 26 (1): 25–40

    Article  PubMed  CAS  Google Scholar 

  96. Yonkers K, Gillespie JA. Quality of life impairment and response in PMDD [poster]. 155th Annual APA Meeting; 2002 May 18–23, Philadelphia

    Google Scholar 

  97. Kraemer GR, Kraemer RR. Premenstrual syndrome: diagnosis and treatment experiences. J Womens Health 1998; 7: 893–907

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author has received previous grant support for antidepressant treatment of PMS/PMDD from Pfizer, Lilly, Wyeth, Forest and SmithKline Beecham. No outside sources of funding were used for the preparation of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ellen W. Freeman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freeman, E.W. Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder. Pharmacoeconomics 23, 433–444 (2005). https://doi.org/10.2165/00019053-200523050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200523050-00003

Keywords

Navigation